Profound Medical Corp
TSX:PRN

Watchlist Manager
Profound Medical Corp Logo
Profound Medical Corp
TSX:PRN
Watchlist
Price: 10.03 CAD 0.3%
Market Cap: 247.4m CAD
Have any thoughts about
Profound Medical Corp?
Write Note

Profound Medical Corp
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Profound Medical Corp
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Profound Medical Corp
TSX:PRN
Accounts Receivables
$6.9m
CAGR 3-Years
-2%
CAGR 5-Years
59%
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Accounts Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Opsens Inc
TSX:OPS
Accounts Receivables
CA$8.9m
CAGR 3-Years
32%
CAGR 5-Years
26%
CAGR 10-Years
25%
Theralase Technologies Inc
XTSX:TLT
Accounts Receivables
CA$264.2k
CAGR 3-Years
7%
CAGR 5-Years
-18%
CAGR 10-Years
-8%
MedMira Inc
XTSX:MIR
Accounts Receivables
CA$1.3m
CAGR 3-Years
2%
CAGR 5-Years
102%
CAGR 10-Years
5%
O
Ondine Biomedical Inc
LSE:OBI
Accounts Receivables
CA$326k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Profound Medical Corp
Glance View

Market Cap
247.4m CAD
Industry
Health Care

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

PRN Intrinsic Value
5.75 CAD
Overvaluation 43%
Intrinsic Value
Price

See Also

What is Profound Medical Corp's Accounts Receivables?
Accounts Receivables
6.9m USD

Based on the financial report for Sep 30, 2024, Profound Medical Corp's Accounts Receivables amounts to 6.9m USD.

What is Profound Medical Corp's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
59%

Over the last year, the Accounts Receivables growth was 9%. The average annual Accounts Receivables growth rates for Profound Medical Corp have been -2% over the past three years , 59% over the past five years .

Back to Top